UTHSCSA - Faculty Profiles

Search All | Profile | Publications | Grants | Faculty Index

DeFronzo, Ralph A

School of Medicine
Medicine
(210) 567-6691
albarado@uthscsa.edu

My major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus, the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders-known collectively as the Insulin Resistance Syndrome, and the etiology and treatment of diabetic nephropathy. Using the euglycemic insulin clamp technique in combination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, I have helped to define the biochemical and molecular disturbances responsible for insulin resistance in type 2 diabetes mellitus.

Appointments Education Expertise Publications Grants

12/1994 - Present	Deputy Director	Texas Diabetes Institute, San Antonio, TX
12/1988 - Present	Staff Physician	South Texas Veterans Health Care System - Audie L. Murphy Division, San Antonio, TX
9/1988 - Present	Professor	UTHSCSA, Medicine/Diabetes, San Antonio, TX
9/1988 - Present	Director, Diabetes Outpatient Education Program	STVHCS, ALMD, San Antonio, TX
9/1988 - Present	Division Chief - Diabetes and Division Chief - Diabetes	UTHSCSA, Medicine/Diabetes, San Antonio, TX
9/1988 - Present	Director and Diabetes Research Unit	GCRC, UTHSCSA, San Antonio, TX

Journal Article

Liang H, Balas B, Tantiwong P, Dube J, Goodpaster BH, O''Doherty RM, DeFronzo RA, Richardson A, Musi N, Ward WF. Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity Am J Physiol Endocrinol Metab 2009 Apr;296(4):945-954.

Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial Diabetologia 2009 Apr;52(4):723-732.

Liang H, Balas B, Tantiwong P, Dube JJ, Goodpaster BH, ODoherty RM, Defronzo RA, Richardson A, Musi N, Ward, WF. Whole-Body Overexpression of PGC-1{alpha} Has Opposite Effects on Hepatic and Muscle Insulin Sensitivity Am J Physiol Endocrinol Metab 2009 Apr;296:E945-E954.

Chavez AO, Coletta DK, Kamath S, Cromack D, Monroy A, Folli F, Defronzo RA, Tripathy D. Retinol binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in mexican americans Am J Physiol Endocrinol Metab 2009 Apr;269(4):E758-764.

Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance Diabetes 2009 Feb;58(2):337-343.

Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study Diabetes Care 2009 Feb;32(2):281-286.

Gastaldelli A, Perego L, Paganelli M, Sesti G, Hribal M, Chavez AO, Defronzo RA, Pontiroli A, Folli F. Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding Obes Surg 2009 Jan;19(1):80-86.

Coletta DK, Schneider J, Hu SL, Dyer TD, Puppala S, Farook VS, Arya R, Lehman DM, Blangero J, DeFronzo RA, Duggirala R, Jenkinson CP. Genome-wide linkage scan for genes influencing plasma triglyceride levels in the Veterans Administration Genetic Epidemiology Study Diabetes 2009 Jan;58(1):279-284.

DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 Dec;31(12):2315-2317.

Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients Diabetes Obes Metab 2008 Dec;10(12):1204-1211.

Abdul-Ghani MA, Matsuda M, DeFronzo RA. Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects Diabet Med 2008 Nov;25(11):1289-1294.

Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, Defronzo RA, Coletta DK, Sriwijitkamol A, Musi N. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects Diabetes 2008 Oct;57(10):2595-2602.

Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, Chang Z, Tripathy D, Jani R, Molina-Carrion M, Monroy A, Folli F, Van Remmen H, DeFronzo RA. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance Am J Physiol Endocrinol Metab 2008 Sep;295(3):678-685.

Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA, Abdul-Ghani M. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes Diabetes Care 2008 Aug;31(8):1650-1655.

Miyazaki Y, Akasaka H, Ohnishi H, Saitoh S, DeFronzo RA, Shimamoto K. Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects Hypertens Res 2008 Jul;31(7):1357-1363.

Jenkinson CP, Coletta DK, Flechtner-Mors M, Hu SL, Fourcaudot MJ, Rodriguez LM, Schneider J, Arya R, Stern MP, Blangero J, Duggirala R, DeFronzo RA. Association of genetic variation in ENPP1 with obesity-related phenotypes Obesity (Silver Spring) 2008 Jul;16(7):1708-1713.

Abdul-Ghani MA, DeFronzo RA, Abdul-Ghani M. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus Curr Diab Rep 2008 Jun;8(3):173-178.

Abdul-Ghani M, Matsuda M, Jani R, Jenkinson CP, Richardson DK, Kaku K, Defronzo RA. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance Am J Physiol Endocrinol Metab 2008 May;.

Coletta DK, Balas B, Chavez AO, Baig M, Abdul-Ghani M, Kashyap SR, Folli F, Tripathy D, Mandarino LJ, Cornell JE, Defronzo RA, Jenkinson CP. Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo Am J Physiol Endocrinol Metab 2008 May;294(5):910-917.

Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, Tantiwong P, Voruganti VS, Musi N, Comuzzie AG, DeFronzo RA, Folli F. Physiological and molecular determinants of insulin action in the baboon Diabetes 2008 Apr;57(4):899-908.

Betteridge DJ, Defronzo RA, Chilton RJ. PROactive: time for a critical appraisal Eur Heart J 2008 Apr;29(8):969-983.

Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, Defronzo RA, Cersosimo E. Mechanism of Action of Exenatide to Reduce Postprandial Hyperglycemia In Type 2 Diabetes Am J Physiol Endocrinol Metab 2008 Mar;.

Abdul-Ghani MUHAMMAD, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RALPH, Jenkinson CP. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin Acta Diabetol 2008 Mar;.

Thomaseth K, Pavan A, Berria R, Glass L, DeFronzo R, Gastaldelli A, DeFronzo RA. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test Comput Methods Programs Biomed 2008 Feb;89(2):132-140.

Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo RA, Abdul-Ghani M. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range Diabetes Care 2008 Feb;31(2):311-315.

Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma arginase activity in type 2 diabetic patients Diabetes Care 2008 Jan;31(1):134-139.

Miyazaki Y, Cersosimo E, Triplitt C, Defronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients Kidney Int 2007 Sep;.

Wang L, Balas B, Christ-Roberts CY, Kim RY, Ramos FJ, Kikani CK, Li C, Deng C, Reyna S, Musi N, Dong LQ, DeFronzo RA, Liu F. Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo Mol Cell Biol 2007 Sep;27:6497-6505.

Gastaldelli A., Cusi K., Pettiti M., Hardies LJ, Miyazaki Y., Berria, R., Buzzigoli E., Sironi AM., Cersosimo E., Ferrannini E., Defronzo RA. Relationship between hepatic insulin resistance in nondiabetic and type 2 diabetic subjects Gastroenterology 2007 Aug;:496-506.

Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 2007 Jun;30(6):1544-1548.

Coletta DK, Schneider J, Stern MP, Blangero J, DeFronzo RA, Duggirala R, Jenkinson CP. Association of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican Americans Obesity 2007 Apr;15(4):809-815.

Wajcberg E, Sriwijitkamol A, Musi N, DeFronzo RA, Cersosimo E. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone J Clin Endocrinol Metab 2007 Apr;92(4):1256-1262.

Sriwijitkamol A, Coletta DK, Wajcberg E, Balbontin GB, Reyna SM, Barrientes J, Eagan PA, Jenkinson CP, Cersosimo E, Defronzo RA, Sakamoto K, Musi N. Effect of Acute Exercise on AMPK Signaling in Skeletal Muscle of Subjects With Type 2 Diabetes: A Time-Course and Dose-Response Study Diabetes 2007 Mar;56(3):836-848.

Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations Diab Vasc Dis Res 2007 Mar;4(1):13-19.

Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, Defronzo RA, Mandarino LJ. Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free Fatty Acid concentration Diabetes 2007 Mar;56(3):743-752.

Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus Clin Pharmacol Ther 2007 Mar;82(3):275-281.

Nathan DM, Davidson MB, Defronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care Diabetes Care 2007 Mar;30(3):753-759.

Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, Defronzo RA. Thiazolidinediones Improve Beta-Cell Function in Type 2 Diabetic Patients Am J Physiol Endocrinol Metab 2007 Mar;292(3):871-883.

Abdul-Ghani M, Defronzo RA. Fasting Hyperglycemia Impairs Glucose- but not Insulin-Mediated Suppression of Glucagon Secretion J Clin Endocrinol Metab 2007 Feb;.

Hendee WR, Banovac F, Carson PL, DeFronzo RA, Eckelman WC, Fullerton GD, Larson SM, McLennan G, Welch MJ. Biomedical imaging research opportunities workshop IV: a white paper Med Phys 2007 Feb;34(2):673-679.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, Defronzo RA. The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single Dose Administration in Type 2 Diabetic Patients J Clin Endocrinol Metab 2007 Jan;92:1249-1255.

Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test Diabetes Care 2007 Jan;30(1):89-94.

Pendergrass M, Bertoldo A, Bonadonna R, Nucci G, Mandarino L, Cobelli C, Defronzo RA. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals Am J Physiol Endocrinol Metab 2007 Jan;292(1):92-100.

Jani R, Triplitt C, Reasner C, Defronzo RA. First approved inhaled insulin therapy for diabetes mellitus Expert Opin Drug Deliv 2007 Jan;4(1):63-76.

Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea Horm Metab Res 2006 Dec;38(12):838-844.

Schimmack G, Defronzo RA, Musi N. AMP-activated protein kinase: Role in metabolism and therapeutic implications Diabetes Obes Metab 2006 Nov;8(6):591-602.

Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases Diabetes Metab Res Rev 2006 Nov;22(6):423-436.

Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA. The effect of pioglitazone on the liver: role of adiponectin Diabetes Care 2006 Oct;29(10):2275-2281.

Richardson DK, Schneider J, Fourcaudot MJ, Rodriguez LM, Arya R, Dyer TD, Almasy L, Blangero J, Stern MP, Defronzo RA, Duggirala R, Jenkinson CP. Association between variants in the genes for adiponectin and its receptors with insulin resistance syndrome (IRS)-related phenotypes in Mexican Americans Diabetologia 2006 Oct;49(10):2317-2328.

Defronzo RA. Is insulin resistance atherogenic? Possible mechanisms Atheroscler Suppl 2006 Aug;7(4):11-15.

Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, Ravussin E, Smith SR. Role of adiponectin in human skeletal muscle bioenergetics Cell Metab 2006 Jul;4(1):75-87.

Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, Defronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study Diabetes 2006 May;55(5):1430-1435.

Arya R, Demerath E, Jenkinson CP, Gring HH, Puppala S, Farook V, Fowler S, Schneider J, Granato R, Resendez RG, Dyer TD, Cole SA, Almasy L, Comuzzie AG, Siervogel RM, Bradshaw B, DeFronzo RA, MacCluer J, Stern MP, Towne B, Blangero J, Duggirala R. A quantitative trait locus (QTL) on chromosome 6q influences birth weight in two independent family studies Hum Mol Genet 2006 May;15(10):1569-1579.

Sriwijitkamol A, Ivy JL, Christ-Roberts C, DeFronzo RA, Mandarino LJ, Musi N. LKB1-AMPK signaling in muscle from obese insulin-resistant Zucker rats and effects of training Am J Physiol Endocrinol Metab 2006 May;290(5):925-932.

Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, OMahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: Diabetes Care 2006 May;29(5):1016-1023.

Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose Diabetes Care 2006 May;29(5):1130-1139.

Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, Defronzo RA, Ferrannini E, Gastadelli A. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes J Clin Endocrinol Metab 2006 Mar;91(3):806-812.

Sriwijitkamol A, Christ-Roberts C, Berria R, Eagan P, Pratipanawatr T, DeFronzo RA, Mandarino LJ, Musi N. Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training Diabetes 2006 Mar;55(3):760-767.

Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients Diabetes 2005 Nov;54(11):3148-3153.

Abdul-Ghani MA, DeFronzo RA. To: Godsland IF, Jeffs JA, Johnston DG (2004) loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157-1166 Diabetologia 2005 Oct;48(10):2187-2188.

DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial Diabetes Care 2005 Aug;28(8):1922-1928.

Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, Defronzo RA, Cusi K. Dose-response effect of elevated plasma free fatty acid on insulin signaling Diabetes 2005 Jun;54(6):1640-1648.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 May;28(5):1092-1100.

Richardson DK, Kashyap S, Bajaj M, Cusi K, Mandarino SJ, Finlayson J, DeFronzo RA, Jenkinson CP, Mandarino LJ. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle J Biol Chem 2005 Mar;280(11):10290-10297.

Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP, Williams KL. Identification of individuals with insulin resistance using routine clinical measurements Diabetes 2005 Feb;54(2):333-339.

Triplitt C, DeFronzo RA. Exenatide: A Viewpoint by Curtis Triplitt and Ralph A. DeFronzo Drugs 2005 Jan;65(12):1693-1695.

Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms Am Heart J 2005 Jan;149(1):33-45.

Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: evaluation of pathological and therapeutic outcomes Am Heart J 2005 Jan;149(1):20-32.

Kashyap, S.R., Roman, L.J., Lamont, J., MASTERS, B.S.S., Bajaj, M., Suraamornkul, S., Belfort, R., Berria, R., Kellogg Jr., D.L., Liu, Y., and DeFronzo, R.A. Insulin Resistantce Is Associated with Impaired Nitric Oxide Synthase Activity in Skeletal Muscle of Type 2 Diabetic Subjects J. Clin. Endocrinol. Metab 2005 Jan;90(2):1100-1105.

Kashyap SR, Roman LJ, Lamont J, Masters BS, Bajaj M, Suraamornkul S, Belfort R, Berria R, Kellogg Jr DL, Liu Y and DeFronzo RA. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects J Clin Endocrinol Metab 2005 Jan;90(2):1100-1105.

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis J Clin Endocrinol Metab 2005 Jan;90(1):493-500.

Chiquette E, Ramirez G, Defronzo R, DeFronzo RA. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Intern Med 2004 Oct;164(19):2097-2104.

DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes Int J Clin Pract Suppl 2004 Oct;(143):9-21.

Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K, DeFronzo RA. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes Am J Physiol Endocrinol Metab 2004 Sep;287(3):537-546.

Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes J Clin Endocrinol Metab 2004 Sep;89(9):4649-4655.

Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 2004 Sep;89(9):4312-4319.

Gastaldelli A, Miyazaki Y, Pettiti M, Buzzigoli E, Mahankali S, Ferrannini E, DeFronzo RA. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis J Clin Endocrinol Metab 2004 Aug;89(8):3914-3921.

DeFronzo RA. Pathogenesis of type 2 diabetes mellitus Med Clin North Am 2004 Jul;88(4):787-835.

Fanning EL, Selwyn BJ, Larme AC, DeFronzo RA. Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population Diabetes Care 2004 Jul;27(7):1638-1646.

Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazaone-treated type II diabetic patients International Journal of Obesity & Related Metabolic Disorders: Journal of the International Associa 2004 Jun;28(6):783-789.

Civitarese AE, Jenkinson CP, Coletta DK, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ, Ravussin E. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes Diabetologia 2004 May;47(5):816-820.

Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach J Clin Endocrinol Metab 2004 Feb;89(2):463-478.

Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients Journal of Clinical Endocrinology & Metabolism 2004 Jan;89(1):200-206.

Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study Diabetologia 2004 Jan;47(1):31-39.

Adams JM, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans Diabetes 2004 Jan;53(1):25-31.

Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW. Nephropathy in diabetes Diabetes Care 2004 Jan;27 Su:79-83.

Abstract

DeFronzo RA, Banerji MA, Bray GA, Clement S, Tripathy D Henry RR, Mudaliar S, Musi N, Kitabchi A, Ratner R, Schwenke D, Reaven P, Stenz F. Reduced Insulin Secretion/Insulin Resistance (Disposition) Index Predicts Future Diabetes: Results from the ACT NOW Study; 2009 Jun. (Diabetes; vol. 58, no. A419).

Chavez-Velazquez AO,Guardado-Mendoza R, Iannucci CV, Folli F, Kamath S, Defronzo RA, Tripathy D. Plasma insulin and glucagon responses to a maximal hyperglycemic stimulus and arginine infusion in subjects with impaired glucose tolerance and type 2 diabetes mellitus; 2009 Jun. (Diabetes; vol. 58, no. A379).

Guardado- Mendoza R, Chavez-Velazquez AO, Folli F, Iannucci CV, Defronzo RA, Tripathy D. Reduced Amylin (IAPP) Secretion in Response to Hyperglycemia and Arginine are Characteristic of Impaired Glucose Tolerance and Type 2 Diabetes; 2009 Jun. (Diabetes; vol. 58, no. A419).

DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Tripathy D. Reduced insulin secretion/insulin resistance (disposition) index is the primary determinant of glucose intolerance in the pre-diabetic state: results fom the ACT NOW Study; 2008 Sep. (Diabetologia; vol. 51, no. A650).

Tripathy D, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Stenz F, DeFronzo RA. Actos Now for the Prevention of Diabetes (ACT NOW) Study; 2008 Sep. (Diabetologia; vol. 51, no. A224).

Abdul-Ghani M, Jani R, Chavez-Velazquez AO, Molina M, Tripathy D, DeFronzo RA. Mitochondrial reactive oxygen species generation in obese non-diabetic and T2DM subjects; 2008 Sep. (Diabetologia; vol. 51, no. A620).

Wang C-P, Haffner SM, DeFronzo RA, Pugh J. "Add-on oral agents and cardiovascular diseases in VA patients"; 2008 Jun. (Diabetes; vol. 57, no. Su 1).

Wang C-P, Haffner SM, DeFronzo RA, Pugh J. "Differential rosiglitazone effects on cardiovascular diseases in VA type 2 diabetes patients"; 2008 Jun. (Diabetes; vol. 57, no. Su 1).

DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Tripathy D. Reduced Insulin Secretion/Insulin Resistance (Disposition) Index is the Primary Determinant of Glucose Intolerance in the Pre-diabetic State: Results from ACT NOW; 2008 Jun. (Diabetes; vol. 57, no. A45).

Abdul-Ghani MA, Jani R, Chavez-Velazquez AO, Molina-Carrion M, Defronzo RA, Tripathy D. Decreased Mitochondrial ATP Synthesis in Obese Non-Diabetic Subjects; 2008 Jun. (Diabetes; vol. 57, no. A365).

DeFronzo RA, Banerji M, Bray G, Buchanan T, Clement S, Henry R, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Tripathy D. Adipocyte insulin resistance in impaired glucose tolerance: Results from ACT NOW; 2008 Jun. (Diabetes; vol. 57, no. A384).

Monroy A, Carroll C, Chavez AO, Barrentine A, Abdul-Ghani MA, Tripathy D, Weintraub S, DeFronzo RA, Folli F. Mitochondrial proteomics of human type 2 diabetic skeletal muscle reveals downregulation of selected respiratory chain components; 2008 Jun. (Diabetes; vol. 57, no. A429).

DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry R, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Tripathy D. Insulin Secretion and Insulin Sensitivity in Hispanic, African-American and Caucasian Subjects with Impaired Glucose Tolerance (IGT): Results from ACT NOW; 2008 Jun. (Diabetes; vol. 57, no. A664).

Chavez AO, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo RA, Tripathy D. Fibroblast growth factor-21 (FGF-21), a novel peptide, is associated with whole body and hepatic insulin resistance; 2008 Jun. (Diabetes; vol. 57, no. A33).

Tantiwong, Puntip, Shanmugasundaram K, Sriwijitkamol A, Cersosimo E, DeFronzo RA, Mohan S, Musi N. NFκB activity in muscle of type-2 diabetic subjects: Effect of acute exercise; 2008 Jan. (American Diabetes Association National Meeting).

Tripathy D, Banerji M, Buchanan T, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, DeFronzo RA. ACT NOW Study; 2007 Jun. (Diabetes; vol. 56, no. A572).

Chavez-Velazquez A, Jani R, Abdul-Ghani M, Frohlich V, Padma S, Jenkinson CP, Folli F, DeFronzo RA, Tripathy D. Short-term elevation of plasma free fatty acids (FFA) decreases skeletal muscle mitochondrial membrane potential in healthy glucose tolerant subjects; 2007 Jun. (Diabetes; vol. 56, no. A63).

Abdul-Ghani MA, Muller FL, Liu YH, Chavez-Velazquez AO, Balas B, Tripathy D, Jani R, Monroy A, Van Remmen H, DeFronzo RA. Deleterious effect of elevated fatty acid metabolites concentration on skeletal muscle mitochondrial ATP synthesis; 2007 Jun. (Diabetes; vol. 56, no. A337).

Belfort R.S., Brown K., Darland C., Finch J., Tio, F., Gastaldelli A., Hardies LJ, Berria R., Dwivedi S., Havranek R., Balas B., Fincke C., DeFronzo RA, Cusi K, Harrison S. Role of Pioglitazone (PIO) in Patients with Non-Alcoholic Steatohepatitis (NASH); 2005 Feb. (European Association for the Study of Diabetes (EASD)).

Triplitt CL, Glass L, Miyazaki Y, Wajcberg E, Franz D, Cersosimo E, DeFronzo R. Addition of Glargine Insulin Versus Rosiglitazone in Diabetic Subjects Poorly COntrolled on Maximum Dose Metformin/Sulfonylurea Therapy; 2004 Jan. (Diabetes).

Not Specified

Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents Diabetes Care 2008 Nov;31(11):2177-2182.

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 2008 Oct;24(10):2943-2952.

Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E, DeFronzo RA. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease J Am Soc Nephrol 2008 Jan;19(1):182-187.

Federal
Funding Agency	NIH
Title	NIH - Regulation of Hepatic and Peripheral Glucose Metabolism
Status	Active
Period	7/2006 - 6/2011
Role	Principal Investigator
Grant Detail
Funding Agency	NIH/NIDDK
Title	Heterogeneity, Glycemic Control & Macro-Vascular Complications in Type 2 Diabetes
Status	Active
Period	6/2006 - 5/2011
Role	Contributor
Grant Detail	The primary purpose of this proposal is to support an integrated program of training and research to develop an independent research career in statistical methods pertinent to the design and testing of interventions aimed at reducing diabetes-related cardiovascular disease for patients with type II diabetes.
Funding Agency	Veterans Administration
Title	Pathogenesis of Type 2 Diabetes: Lipotoxicity & Mitochondrial Dysfunction
Status	Active
Period	10/2005 - 9/2009
Role	Principal Investigator
Grant Detail
Funding Agency	VA
Title	Veterans Administration Research Service - Molecular Epidemiology of Type 2 Diabetes Mellitus in Mexican Americans
Status	Active
Period	10/2004 - 9/2009
Role	Principal Investigator
Grant Detail
Private
Funding Agency	American Diabetes Association
Title	American Diabetes Association - Mentor-Based Minority Postdoctoral Fellowship Award
Status	Active
Period	7/2008 - 6/2011
Role	Principal Investigator
Grant Detail
Funding Agency	American Diabetes Association
Title	Durability of early combination therapy vs conventinal therapy in new onset diabetes
Status	Active
Period	7/2008 - 6/2011
Role	Principal Investigator
Grant Detail
Funding Agency	American Diabetes Association
Title	American Diabetes Association - Mentor-Based Postdoctoral Fellowship Award
Status	Active
Period	7/2005 - 6/2009
Role	Principal Investigator
Grant Detail
Funding Agency	deCode genetics Inc
Title	Postdoctoral Fellowship Research Program in the Molecular Basis and Genectics of Type 2 Diabetes and Related Metabolic Diseases
Status	Active
Period	7/2008 - 6/2009
Role	Principal Investigator
Grant Detail
Funding Agency	Kronkosky Charitable Foundation
Title	Effect of Altering Mitochondrial Function on Insulin Resistance in Cultured Human Skeletal Muscle Cells
Status	Active
Period	12/2007 - 11/2008
Role	Principal Investigator
Grant Detail
Funding Agency	American Diabetes Association
Title	American Diabetes Association - Mentor Based Minority Postdoctoral Fellowship
Status	Complete
Period	7/2005 - 6/2008
Role	Principal Investigator
Grant Detail
Funding Agency	Endocrine Fellows Foundation
Title	The Role of PGC-1 in the Development of Hepatic Resistance
Status	Complete
Period	1/2007 - 12/2007
Role	Principal Investigator
Grant Detail
Funding Agency	Endocrine Fellows Foundation
Title	Anti-Inflamatory Effect of Exercise in Skeletal Muscle: Novel Mechanism to Treat Insulin Resistance
Status	Complete
Period	6/2006 - 5/2007
Role	Co-Investigator
Grant Detail
State
Funding Agency	Borderplex Council
Title	Development of Diabetes and Metabolic Syndrome in Hispanics Using Atypical Antipsychotics
Status	Active
Period	8/2008 - 7/2009
Role	Consultant
Grant Detail

Funding Agency
Title	Effect of Pioglitazone treatment on glucose metabolism, a dipose tissue lipolysis and insulin sensitivity, muscle insulin signaling and fat content in patients affected by polycystic ovary syndrome
Status	Active
Period	- Present
Role	Principal Investigator
Grant Detail

Year	Degree	Discipline	Institution
1975	Postdoctoral Fellowship	Renal	Hospital of the University of Pennsylvania Philadelphia , PA
1973	Postdoctoral Fellowship	Endocrinology	Gerontology Research Center, NIMHCD Baltimore , MD
1971	Residency		Johns Hopkins Hospital Baltimore , MD
1970	Internship		Johns Hopkins Hopsital Baltimore , MD
1969	MD	Medicine (Cum Laude)	Harvard Medical School Boston , MA
1969	MMS	Medicine (Cum Laude)	Dartmouth College Graduate School of Biology USA
1967	BMS	Medicine	Dartmouth Medical School Hanover , NH
1964	BS	Biology/Biochemistry	Yale Univeristy New Haven , CT

Faculty

FAQ

Suggestions

DeFronzo, Ralph A

Diabetes

Journal Article

Abstract

Not Specified

Federal

Private

State